טוען...
Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases
Patients with castration-resistant prostate cancer (CRPC) frequently have metastases to the bone, which may cause pain and lead to a deterioration in quality-of-life. Bone-seeking radiopharmaceuticals are agents which, when administered systemically, localize to the site of bone metastases and deliv...
שמור ב:
| Main Authors: | , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2012
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4124611/ https://ncbi.nlm.nih.gov/pubmed/22521546 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.canlet.2012.04.001 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|